Covid-19 Response and Resources
The NH-INBRE leadership is following the NIH guidance in the quickly changing times of the COVID-19 world. We have been monitoring the COVID-19 updates and news from our partners. Dartmouth is also undergoing changes with lab closures and remote scholarly work, so we understand the shifting environment that our Partners are going through as well. Our intention is to provide you all with appropriate guidance as we find out and to provide support in the coming weeks/months.
Q and A
- I am quarantined, self-isolated, or caring for a sick family member can I request an extension to my NH-INBRE annual reporting?
Annual progress reports for all funded faculty, RSTG supported faculty, and Institutional RSTG Leaders are due April 15th. As the progress reporting for NH-INBRE Partners is completed online we will not be issuing an extension for the annual reporting. If you are effected by COVID-19 beyond working remotely and cannot submit the progress report materials by the due date please contact Jennifer Smith.
- I am working remotely from home in self-isolation. Can my effort still be charge to the grant?
If your institution’s policy allows for charging salaries and benefits during periods when no work is performed due to the effect of COVID-19, then such charges to NIH grant awards will be allowable. This includes salary and benefits for RSTG students and staff receiving effort from INBRE. Please have this policy available if documentation is requested by NIH.
- Are travel cancellation costs due to COVID-19 allowable as direct charges to sponsored projects?
Non-refundable costs associated with grant-related travel that has been cancelled due to COVID-19 may be charged to the NIH award if they would have otherwise been allowable. See NIH GPS 7.9.1 for detailed information on the allowability of travel expenses.
Non-refundable registration fees for conferences, symposiums or seminars that have been cancelled due to COVID19 may be charged to the NIH award if they would have otherwise been allowable (e.g. necessary to accomplish program objectives).
Guidance from Federal Sponsors on Grant Related Issues
|Bill & Melinda Gates Foundation||COVID-19 Therapeutics Accelerator will coordinate R&D efforts and remove barriers to drug development and scale-up to address the epidemic|
|Biomedical Advanced Research and Development Authority (BARDA)||Broad agency announcement (BAA) on March 6, 2020 to focus specifically on products to diagnose, prevent or treat coronavirus infections|
|Centers for Disease Control||Centers for Disease Control COVID-19 Broad Agency Announcement|
|Department of Energy||RAPID REQUEST: Coronavirus Disease 2019 (COVID-19) Dear Colleague Letter.
Asking for input on COVID-19 rapid research response involving DOE user facilities and infrastructure.Invitation for COVID-19 scientific questions
|NIH||NIAID’s Multi-Pronged Response to the COVID-2019 OutbreakAdministrative Supplements
New Tool for SARS-CoV-2/COVID-2019 Response
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV)
|NIH||Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)|
|NIH||Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)|
|NSF||Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)|
|NSF||NSF 20-052 Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19)|
|Office of Science and Technology Policy, White House||Release of COVID-19 Open Research Dataset (CORD-19) of scholarly literature about COVID-19, SARS-CoV-2, and the Coronavirus group.
Call to action to the Nation’s artificial intelligence experts to develop new text and data mining techniques that can help the science community answer high-priority scientific questions related to COVID-19.
Call to Action to the Tech Community on New Machine Readable COVID-19 Dataset